表紙
市場調查報告書

抗癌症治療查核點抑制劑的全球市場的預測:2019年∼2029年

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs

出版商 Visiongain Ltd 商品編碼 346762
出版日期 內容資訊 英文 152 Pages
商品交期: 最快1-2個工作天內
價格
抗癌症治療查核點抑制劑的全球市場的預測:2019年∼2029年 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs
出版日期: 2019年05月28日內容資訊: 英文 152 Pages
簡介

全球抗癌症治療查核點抑制劑市場在2018年預計將達到114億3000萬美元,至2029年預計將以年複合成長率 (CAGR) 13.7%的速度成長。

本報告提供全球抗癌症治療查核點抑制劑市場相關調查分析,市場概要,市場分析、預測,各地區、國家的市場機會,開發平台分析,主要企業等相關的系統性資訊。

第1章 報告概要

第2章 全球抗癌症治療查核點抑制劑市場簡介

  • 免疫療法的新時代
  • 腫瘤學治療的查核點抑制劑
  • 適應市場區隔

第3章 抗癌症治療查核點抑制劑市場主要藥物的預測,全球主要企業

  • 主要藥
    • Yervoy (Ipilimumab) :Bristol-Myers Squibb
    • Opdivo (Nivolumab) :Bristol-Myers Squibb/小野藥品工業
    • Keytruda (Pembrolizumab) :Merck & Co.
  • 主要企業
    • Bristol-Myers Squibb先導市場

第4章 抗癌症治療查核點抑制劑:全球市場

  • 全球市場
  • 收益預測
  • 主要的次市場預測

第5章 抗癌症治療查核點抑制劑市場主要國家市場

  • 流行病學
  • 地區的明細
  • 各地區預測
  • 美國
  • 歐洲市場
  • EU
  • 日本
  • 亞太地區

第6章 抗癌症治療查核點抑制劑市場開發平台分析

  • 抗PD-1抑制劑和抗PD-L1抑制劑
  • CTLA-4抑制劑
  • LAG-3 (淋巴球活性化遺傳基因3) 抑制劑
  • KIR抑制劑
  • 抗NKG2A抑制劑
  • 其他查核點抑制劑等

第7章 抗癌症治療查核點抑制劑市場定性分析

  • SWOT分析

第8章 企業簡介

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer Inc.
  • Roche Holding Ag

第9章 結論

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0423

The global checkpoint inhibitors for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 152-page report you will receive 72 tables and 32 figures - all unavailable elsewhere.

The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs:

  • Yervoy (ipilimumab)
  • Opdivo (nivolumab)
  • Keytruda (pembrolizumab)

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class:

  • CTLA-4 Inhibitors
  • PD-1 Inhibitors
  • Pipeline Drugs

Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market:

  • U.S.
  • EU: Germany, France, Italy, U.K., Spain
  • Japan
  • APAC

Profiles of the selected leading companies:

  • AstraZeneca, Plc
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Roche Holding AG
  • The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis
  • A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market

Key Questions Answered by this Report:

  • What are the global revenue prospects for the period 2018 to 2029?
  • What are the leading national market potentials from 2018 to 2029?
  • How is the checkpoint inhibitor anti-cancer treatment drugs market evolving?
  • What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market?
  • What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market?
  • How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
  • Which therapies can succeed and what revenues could they generate to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market. You find data, trends and predictions.

Buy our report today Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs. ’

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2018
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methods of the Study
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer Treatment Drugs World Market 2018

  • 2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
  • 2.2 Checkpoint Inhibitor Treatment Drugs in Oncology
  • 2.3 Application Segment
    • 2.3.1 Lung Cancer
    • 2.3.2 Bladder Cancer
    • 2.3.3 Melanoma
    • 2.3.4 Hodgkin Lymphoma

3. Leading Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market Forecasts 2019-2029 and Leading Companies in the World Market

  • 3.1 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs in the Market 2019
    • 3.1.1 Yervoy (ipilimumab) - Bristol-Myers Squibb
      • 3.1.1.1 Yervoy: Sales Analysis
    • 3.1.2 Opdivo (nivolumab) - Bristol-Myers Squibb/Ono Pharmaceutical
      • 3.1.2.1 Opdivo: Sales Analysis
    • 3.1.3 Keytruda (pembrolizumab) - Merck & Co.
      • 3.1.3.1 Keytruda: Sales Analysis
  • 3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market in 2018
    • 3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment Drugs: World Market 2019-2029

  • 4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2018
  • 4.2 The World Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market: Revenue Forecasts 2019-20
  • 4.3 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs Submarkets Forecast 2019-2029
    • 4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2019-2029
    • 4.3.2 The PD-1 Inhibitors Submarket Forecast 2019-2029
    • 4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
    • 4.3.4 Market Dynamics of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
      • 4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 4.3.4.3 Opportunity of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 4.3.4.4 Trends of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029

  • 5.1 Epidemiology of Major Cancer types
    • 5.1.1 Lung Cancer
    • 5.1.2 Bladder Cancer
    • 5.1.3 Melanoma
    • 5.1.4 Hodgkin Lymphoma
    • 5.1.5 Pancreatic Cancer
  • 5.2 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
  • 5.3 World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Regional Forecast, 2019-2029
    • 5.3.1 How Will Regional Market Shares Change by 2029?
  • 5.4 The US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
  • 5.5 The EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
  • 5.6 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
  • 5.7 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029

6. The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Pipeline Analysis 2019-2029

  • 6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
    • 6.1.1 Tecentriq (Atezolizumab)
    • 6.1.2 Pidilizumab (CT-011) - CureTech, Ltd.
    • 6.1.3 AMP-224 - GSK/Amplimmune
    • 6.1.4 REGN2810 - Regeneron/Sanofi
    • 6.1.5 Libtayo
  • 6.2 CTLA-4 Inhibitors
    • 6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
  • 6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
    • 6.3.1 IMP321- Prima Biomed
    • 6.3.2 BMS-986016 - Bristol-Myers Squibb
    • 6.3.3 IMP701 - Prima BioMed/Novartis
  • 6.4 KIR Inhibitors
    • 6.4.1 Lirilumab (IPH2102/BMS-986015) - Innate Pharma/Bristol-Myers Squibb
  • 6.5 Anti-NKG2A Inhibitors
    • 6.5.1 IPH2201 - Innate Pharma/AstraZeneca/MedImmune
  • 6.6 Other Checkpoint Inhibitors
    • 6.6.1 VISTA Inhibitors
      • 6.6.1.1 CA-170 - Curis Inc/Aurigene Discovery Technologies
      • 6.6.1.2 NLG919 - NewLink Genetics
      • 6.6.1.3 INCB024360 - Incyte/Roche
    • 6.6.2 A2aR Inhibitors
  • 6.6.2.1 HTL-1071 - AstraZeneca/Heptares
  • 6.7 Clinical trial landscape for Immune checkpoint inhibitors
  • 6.8 Clinical trial landscape for pd1/L1 Immune checkpoint inhibitors

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029

  • 7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
    • 7.1.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 7.1.1.1 A Novel Treatment Method that Harnesses the Immune System's Vast Potential
      • 7.1.1.2 Pricing of the Treatments Will Attract Companies
      • 7.1.1.3 Cost of Treatment Will Restrain Market Access
      • 7.1.1.4 Side Effects May Prohibit Growth
    • 7.1.2 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 7.1.2.1 Biomarkers Pave the Way for Optimum Utility
      • 7.1.2.2 Combination Therapies are Achieving Superior Results
      • 7.1.2.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
      • 7.1.2.4 Crowding of the Market with Similar Products

8. Company Profiles

  • 8.1 AstraZeneca Plc.
    • 8.1.1 Company Overview
    • 8.1.2 Key Developments
  • 8.2 Bristol-Myers Squibb Co.
    • 8.2.1 Company Overview
    • 8.2.2 Key Developments
  • 8.3 Celldex Therapeutics Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Key Developments
  • 8.4 Incyte Corporation
    • 8.4.1 Company Overview
    • 8.4.2 Key Developments
  • 8.5 Merck & Co., Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Key Developments
  • 8.6 Novartis Ag
    • 8.6.1 Company Overview
    • 8.6.2 Key Developments
  • 8.7 Pfizer Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Key Developments
  • 8.8 Roche Holding Ag
    • 8.8.1 Company Overview
    • 8.8.2 Key Developments

9. Conclusions

  • 9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Current World Outlook
    • 9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market to 2029
  • 9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2019-2029: The US and EU Will Retain Their Lead
  • 9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2018
  • Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2015-2018
  • Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2024
  • Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2025-2029
  • Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2024-2029
  • Table 3.8 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Revenue ($bn), Market Share (%), 2018
  • Table 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
  • Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2018
  • Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2018
  • Table 4.4 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2018-2024
  • Table 4.5 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2024-2029
  • Table 4.6 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
  • Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
  • Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
  • Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
  • Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
  • Table 4.11 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2018-2024
  • Table 4.12 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2024-2029
  • Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Market Shares (%), 2018
  • Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
  • Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2024-2029
  • Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018-2024
  • Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024-2029
  • Table 5.6 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.7 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.8 EU Market Shares (%), 2018-2024
  • Table 5.9 EU Market Shares (%), 2024-2029
  • Table 5.10 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.11 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.12 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.13 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.14 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.15 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.16 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.17 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.18 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.19 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.24 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.25 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 6.1 Selected Combination Therapies for Atezolizumab, 2018
  • Table 6.2 Tecentriq Forecast: Revenue ($bn), 2018-2024
  • Table 6.3 Tecentriq Forecast: Revenue ($bn), 2024-2029
  • Table 6.4 Libtayo Forecast: Revenue ($bn), 2018-2024
  • Table 6.5 Tremelimumab Forecast: Revenue ($bn), 2018-2024
  • Table 6.6 Tremelimumab Forecast: Revenue ($bn), 2024-2029
  • Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
  • Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
  • Table 8.1 AstraZeneca PLC. Profile 2018
  • Table 8.2: AstraZeneca: Key Developments
  • Table 8.3 Bristol-Myers Squibb Co. Profile 2018
  • Table 8.4: Bristol-Myers Squibb: Key Developments
  • Table 8.5 Celldex Therapeutics Inc. Profile 2018
  • Table 8.6: Celldex Therapeutics: Key Developments
  • Table 8.7 Incyte Corporation Profile 2018 (
  • Table 8.8: Incyte: Key Developments
  • Table 8.9 Merck & Co., Inc. Profile 2018
  • Table 8.10: Merck & Co.: Key Developments
  • Table 8.11 Novartis AG Profile 2018
  • Table 8.12: Novartis: Key Developments
  • Table 8.13 Pfizer Inc. Profile 2018 (
  • Table 8.14: Pfizer: Key Developments
  • Table 8.15: Roche Holding AG Profile 2018 (
  • Table 8.16: Roche: Key Developments
  • Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
  • Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn) Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029

List of Figures

  • Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Segmentation Overview, 2019
  • Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2015-2018
  • Figure 3.2 Yervoy Forecast, Revenue ($bn), 2018-2029
  • Figure 3.3 Opdivo Forecast, Revenue ($bn), 2018-2029
  • Figure 3.4 Keytruda Forecast, Revenue ($bn), 2018-2029
  • Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Revenue: Market Shares, 2018 (%)
  • Figure 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
  • Figure 4.2 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), 2018-2029
  • Figure 4.3 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
  • Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2018-2029
  • Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2018-2029
  • Figure 4.6 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2024
  • Figure 4.7 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2029
  • Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018
  • Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), 2018-2029
  • Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024
  • Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2029
  • Figure 5.5 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.6 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.7 EU Market for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, by Leading Country (%), 2018
  • Figure 5.8 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, Market Sizes ($bn), 2018-2029
  • Figure 5.9 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.10 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.11 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.12 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.13 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.14 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.15 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 6.1 Tecentriq Forecast: Revenue ($bn), 2018-2029
  • Figure 6.2 Tremelimumab Forecast: Revenue ($bn), 2018-2029
  • Figure 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Class: Market Sizes ($bn), 2018-2029
  • Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Region: Market Size ($bn), 2018, 2020, 2024, and 2029

COMPANIES LISTED:

  • AbbVie
  • Abramson Cancer Center
  • Admune Therapeutics
  • Aduro Biotech
  • Advaxis, Inc.
  • Agenus Inc.
  • Agilent Technologies
  • Alcon
  • Amgen
  • Amplimmune
  • AnaptysBio
  • Apexigen, Inc.
  • AREVA Med
  • ARIAD Pharmaceuticals, Inc.
  • Array BioPharma
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Basilea Pharmaceutica Ltd.
  • BeiGene
  • Bristol-Myers Squibb
  • Calithera Biosciences Inc.
  • cCAM Biotherapeutics
  • Celgene
  • Celldex Therapeutics Inc.
  • Chugai
  • Clal Biotech
  • Clovis Oncology, Inc.
  • CoStim Pharmaceuticals
  • CureTech, Ltd.
  • Curis, Inc.
  • Daiichi Sankyo Company, Limited
  • Dako
  • DNAtrix
  • Dynavax
  • Eddingpharm
  • Eisai Co., Ltd.
  • Eli Lilly
  • Exelixis, Inc.
  • GE Healthcare
  • GeneCentric Diagnostics, Inc.
  • Heptares Therapeutics
  • IBM
  • Immune Design
  • Immunocore Limited
  • Immutep
  • Incyte
  • Innate Pharma
  • Inovio Pharmaceuticals
  • IOmet Pharma Ltd.
  • Janssen Biotech, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Kyowa Hakko Kirin
  • MacroGenicS Inc.
  • Medarex
  • MedImmune
  • Medivation, Inc
  • Merck & Co.
  • Merus N.V.
  • Moderna Therapeutics
  • Moffitt Cancer Center
  • MS
  • NanoString Technologies, Inc.
  • NEC Corporation
  • NewLink Genetics
  • Novartis
  • Oncothyreon Inc.
  • Ono Pharmaceutical
  • Peregrine Pharmaceuticals
  • Pfizer, Inc.
  • Plexxikon Inc.
  • Prima Biomed
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Seattle Genetics, Inc.
  • Sosei Group Corporation
  • Surface Oncology
  • Syndax Pharmaceuticals
  • Syros Pharmaceuticals, Inc.
  • TARIS Biomedical LLC
  • TESARO, Inc.
  • TetraLogic Pharmaceuticals Corporation
  • Transgene SA
  • Western Oncolytics
  • Xencor

List of Organisations Mentioned in the Report:

  • Cancer Research Institute
  • Central Social Insurance Medical Council
  • Data Monitoring Committee
  • Early Access to Medicines Scheme
  • European Cancer Congress
  • European Medicines Agency
  • European Organisation for Research and Treatment of Cancer
  • MD Anderson Cancer Center
  • Medicines and Healthcare Products Regulatory Agency
  • Ministry of Health, Labour, and Welfare
  • National Cancer Institute
  • National Institute for Health and Clinical Excellence
  • QIMR Berghofer Medical Research Institute
  • University of Pittsburgh
  • Yamaguchi University